Novo Holdings Protagonist Therapeutics, Inc Transaction History

Novo Holdings

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$12.95 - $49.69 $7.77 Million - $29.8 Million	-600,010 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$25.57 - $44.88 $6.85 Million - $12 Million	-267,714 Reduced 30.85%	600,010 $26.9 Million
Q4 2020 Feb 16, 2021	BUY	$18.49 - $25.13 $1.36 Million - $1.84 Million	73,355 Added 9.23%	867,724 $17.5 Million
Q3 2020 Nov 16, 2020	SELL	$15.19 - $22.4 $452,662 - $667,520	-29,800 Reduced 3.62%	794,369 $15.5 Million
Q2 2020 Aug 14, 2020	BUY	$6.19 - $18.84 $781,611 - $2.38 Million	126,270 Added 18.09%	824,169 $14.6 Million
Q1 2020 May 15, 2020	BUY	$5.4 - $9.22 $1.18 Million - $2.02 Million	218,825 Added 45.68%	697,899 $4.93 Million
Q3 2019 Nov 14, 2019	BUY	$9.41 - $16.56 $4.28 Million - $7.54 Million	455,173 Added 1904.41%	479,074 $5.75 Million
Q2 2019 Aug 14, 2019	BUY	$8.98 - $12.96 $214,630 - $309,756	23,901 New	23,901 $289,000

248

56.7M

76.3K

114K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.93B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Novo Holdings, based on Form 13F filings with the SEC.

Stay updated on Novo Holdings with notifications on news.